Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT218 in prostate cancer
NCT06262139Phase 2Recruiting
- Sponsor
- Songqi Gao
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MT218 (3 cohorts), sponsored by Songqi Gao. Primary endpoint: Detection of aggressive prostate cancer (Gleason score 8 to 10) using MT218 compared to mpMRI and PSMA-PET/CT. Started Jul 2024; status: recruiting.
02
Drugs
MT218
Beyond the preview
Go deeper on NCT06262139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06262139.